Sulfonamide orexin receptor agonists and uses thereof

Abstract

Provided herein are compounds of formula (I), or pharma- ceutically acceptable salts thereof, where R1, R2, R3, R4, A, L1, L2, Y, and Z are as defined herein. Also provided herein are pharmaceutical compositions comprising compounds of formula (I), or pharma- ceutically acceptable salts thereof, and methods of using compounds of formula (I), or pharma- ceutically acceptable salts thereof, for example, in the treatment of diseases or disorders treatable by administration of an orexin agonist. [Formula 1] JPEG2024523488000174.jpg78165

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 215,054, filed June 25, 2021, the contents of which are incorporated herein by reference in their entirety for all purposes. [Background technology]

[0002] Orexin is a neuropeptide that is specifically produced in certain neurons located diffusely in the lateral hypothalamus and its surrounding areas. Orexin consists of two subtypes, namely orexin A and orexin B. Both orexin A (OX-A) and orexin B (OX-B) are endogenous ligands of orexin receptors that are mainly present in the brain. Two orexin receptors have been cloned and characterized in mammals. They belong to the superfamily of G protein-coupled receptors. The orexin-1 receptor (OX or OX1R) is partially selective for OX-A, while the orexin-2 receptor (OX2 or OX2R) can bind to OX-A and OX-B with similar affinity. The physiological actions that are presumed to involve orexin are thought to be expressed as two subtypes of orexin receptors via one or both of the OX1 and OX2 receptors.

[0003] Orexins regulate states of sleep and wakefulness, making the orexin system a target for potential therapeutic approaches to treat sleep disorders. Orexins have been shown to stimulate feeding in rats, suggesting a physiological role for these peptides as mediators in central feedback mechanisms regulating feeding behavior. Orexins have also been shown to play roles in wakefulness, emotion, energy homeostasis, reward, learning and memory.

[0004] There is a need for compounds that modulate the orexin receptor, as well as compositions and methods for treating diseases or disorders treatable by administration of orexin agonists. Summary of the Invention

[0005] The present disclosure is directed to compounds that are agonists of the orexin-2 receptor, and pharmaceutical compositions thereof, and their use in treating diseases or disorders treatable by administration of an orexin agonist.

[0006] In one aspect, provided herein is a compound of formula (I): [ka] or a pharma- ceutically acceptable salt or N-oxide thereof; During the ceremony, A is heteroaryl; L 1 -O-, -CR 5 R 6 - or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, Y is cycloalkyl, heterocyclyl, heteroaryl or aryl; Z is absent, heteroaryl or aryl; L 1 But, bond or CR 5 R 6 where Z is heteroaryl or aryl, the compound is [ka] Provided that:

[0007] In one aspect, provided herein is a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, A is heteroaryl; L 1 -O-, -CR 5 R 6 - or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, Y is cycloalkyl, heterocyclyl, heteroaryl or aryl; Z is absent, heteroaryl or aryl; L 1 But, bond or CR 5 R 6 where Z is heteroaryl or aryl, the compound is [ka] Provided that:

[0008] In some embodiments, the present disclosure provides a compound of formula (IA) [ka] or a pharma- ceutical acceptable salt thereof, wherein o, A, L 1 , L 2 , R 1 , R 2 , R 3 , R 4 , and R B is defined herein.

[0009] In some embodiments, the present disclosure provides a compound of formula (IAI) [ka] or a pharma- ceutical acceptable salt thereof, wherein o, A, L 1 , L 2 , R 1 , R 2 , R 3 , R 4 , and R B is defined herein.

[0010] In some embodiments, the present disclosure provides a compound of formula (IB): [ka] or a pharma- ceutical acceptable salt thereof, wherein o, q, A, L 2 , R 1 , R 2 , R 3 , R 4 , R A , R B is defined herein.

[0011] In some embodiments, the present disclosure provides pharmaceutical compositions comprising one or more compounds of the present disclosure, or pharma- ceutically acceptable salts thereof, and a pharma- ceutically acceptable carrier.

[0012] In some embodiments, the present disclosure provides pharmaceutical compositions comprising one or more compounds of the present disclosure, or pharma- ceutically acceptable salts or N-oxides thereof, and a pharma- ceutically acceptable carrier.

[0013] In some embodiments, the present disclosure provides a method for treating a disease or disorder treatable by administration of an orexin agonist, the method comprising administering a therapeutically effective amount of one or more compounds of the present disclosure or a pharma- ceutical acceptable salt thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Throughout this disclosure, various patents, patent applications, and publications are referenced. The disclosures of these patents, patent applications, and publications in their entireties are incorporated by reference into this disclosure for all purposes in order to more fully describe the state of the art known to those skilled in the art as of the date of this disclosure. In the event of any inconsistency between the aforementioned patents, patent applications, and publications and this disclosure, the present disclosure shall control.

[0015] definition For convenience, certain terms employed in the specification, examples, and claims are collected here. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0016] The term "about" immediately preceding a numerical value means a range (e.g., ±10% of that value). For example, unless otherwise indicated in the context of this disclosure or inconsistent with such an interpretation, "about 50" can mean 45 to 55, "about 25,000" can mean 22,500 to 27,500, etc. For example, in a list of numerical values, e.g., "about 49, about 50, about 55, ...", "about 50" means a range that spans less than half the interval(s) of the values ​​before and after it, e.g., a range of more than 49.5 and less than 50.5. Furthermore, the expression "about" "less than" a value or "about" "greater than" a value should be understood in light of the definition of the term "about" provided herein. Similarly, the term "about" before a series of numerical values ​​or a range of values ​​(e.g., "about 10, 20, 30" or "about 10 to 30") refers to all values ​​in the series, or to the endpoints of the range, respectively.

[0017] As used herein, the terms "administer," "administering," or "administration" refer to administering a compound or a pharma- ceutically acceptable salt of the compound, or a composition or formulation containing the compound or a pharma- ceutically acceptable salt of the compound, to a patient.

[0018] The term "pharmaceutically acceptable salts" includes both acid and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting an active compound that functions as a base with an inorganic or organic acid to form a salt, such as, for example, hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, and the like. Examples of base addition salts include, but are not limited to, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris-(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids such as lysine and arginine dicyclohexylamine, etc. Examples of metal salts include lithium salts, sodium salts, potassium salts, magnesium salts, calcium salts, etc. Examples of ammonium salts and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts, etc. Examples of organic bases include lysine, arginine, guanidine, diethanolamine, choline, etc. Those skilled in the art will further recognize that acid addition salts can be prepared by reacting the compound with the appropriate inorganic or organic acid by any of a number of known methods.

[0019] As used herein with respect to a patient, the term "treating" refers to improving at least one symptom of the patient's disorder. Treatment can be improving or at least partially improving the disorder or a symptom associated with the disorder.

[0020] The terms "effective amount" and "therapeutically effective amount" are used interchangeably in this disclosure and refer to an amount of a compound, or a salt thereof, (or a pharmaceutical composition containing said compound or salt), capable of achieving an intended result when administered to a patient. The "effective amount" will vary depending on the active ingredient, the condition, disease, or condition being treated and its severity, as well as the age, weight, health and responsiveness of the mammal being treated.

[0021] The term "therapeutically effective" as applied to a dose or amount refers to that amount of a compound or pharmaceutical formulation sufficient to result in a desired clinical benefit following administration to a patient in need thereof.

[0022] The term "carrier" or "vehicle" as used interchangeably herein includes carriers, excipients, adjuvants, and diluents or any combination of the foregoing and refers to a substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulant, involved in carrying or transporting a pharmaceutical agent from one organ or part of the body to another organ or part of the body. In addition to adjuvants, excipients, and diluents known to those skilled in the art, such carriers include organic and inorganic nanoparticles.

[0023] When a range of values ​​is listed, it is intended to encompass each value and subrange within the range. For example, "C 1 -C 6 Alkyl" is C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5, and C 5-6 Alkyl is intended to be included.

[0024] "Alkyl" or "alkyl group" refers to a fully saturated straight or branched hydrocarbon chain having from 1 to 12 carbon atoms and attached to the remainder of the molecule by a single bond. Alkyl containing any number of carbon atoms from 1 to 12 is included. Alkyl containing up to 12 carbon atoms is defined as C 1 -C 12 Alkyl, and alkyl containing up to 10 carbon atoms is C 1 -C 10 Alkyl, and alkyl containing up to 6 carbon atoms is C 1 -C 6 Alkyl, and alkyl containing up to 5 carbon atoms is C 1 -C 5 It is an alkyl group. 1 -C 5 As alkyl, C 5 Alkyl, C 4 Alkyl, C 3 Alkyl, C 2 Alkyl and C 1 Alkyl (i.e., methyl). 1 -C 6 Alkyl includes the above C 1 -C 5 All parts related to alkyl and C 6 Contains alkyl. 1 -C 10 Alkyl includes the above C 1 -C 5 Alkyl and C 1 -C 6 All parts related to alkyl and C 7 , C 8 , C 9 and C 10 Similarly, C 1 -C 12 Alkyl includes all of the above moieties, as well as C 11 and C 12 Contains alkyl. 1 -C 12Non-limiting examples of alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise in the specification, an alkyl group may be optionally substituted.

[0025] "Alkylene" or "alkylene chain" refers to a fully saturated, straight or branched divalent hydrocarbon chain radical having one to twelve carbon atoms. 1 -C 12 Non-limiting examples of alkylene include methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group (e.g., those described herein) through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise in the specification, an alkylene chain can be optionally substituted.

[0026] "Alkenyl" or "alkenyl group" refers to a straight or branched hydrocarbon chain having from 2 to 12 carbon atoms and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the remainder of the molecule by a single bond. Alkenyl groups containing any number of carbon atoms from 2 to 12 are included. Alkenyl groups containing up to 12 carbon atoms include those having C 2 -C 12 Alkenyl containing up to 10 carbon atoms is C 2 -C 10 alkenyl, and the alkenyl group containing up to 6 carbon atoms is C 2 -C 6 Alkenyl containing up to 5 carbon atoms is C 2 -C 5 Alkenyl. 2 -C 5 Alkenyl includes C 5 Alkenyl, C 4 Alkenyl, C 3Alkenyl, and C 2 Contains alkenyl. 2 -C 6 Alkenyl includes the above C 2 -C 5 All parts related to alkenyl and C 6 Contains alkenyl. 2 -C 10 Alkenyl includes the above C 2 -C 5 Alkenyl and C 2 -C 6 All parts related to alkenyl and C 7 , C 8 , C 9 and C 10 Alkenyl is also included. 2 -C 12 Alkenyl includes all of the moieties listed above, as well as C 11 and C 12 Contains alkenyl. 2 -C 12Non-limiting examples of alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, and 3-nonenyl. , 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise in the specification, an alkyl group may be optionally substituted.

[0027] "Alkenylene" or "alkenylene chain" refers to an unsaturated, linear or branched divalent hydrocarbon chain radical having one or more olefins and 2 to 12 carbon atoms. 2 -C 12 Non-limiting examples of alkenylene include ethylene, propenylene, n-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group (e.g., those described herein) through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise in this specification, the alkenylene chain can be optionally substituted.

[0028] "Alkynyl" or "alkynyl group" refers to a straight or branched hydrocarbon chain having from 2 to 12 carbon atoms and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the remainder of the molecule by a single bond. Alkynyl groups containing any number of carbon atoms from 2 to 12 are included. Alkynyl groups containing up to 12 carbon atoms include C 2 -C 12 Alkynyl containing up to 10 carbon atoms is C 2 -C 10 Alkynyl, an alkynyl group containing up to 6 carbon atoms is C 2 -C 6 Alkynyl containing up to 5 carbon atoms is C 2 -C 5 Alkynyl. 2 -C 5 Alkynyl includes C 5 Alkynyl, C 4 Alkynyl, C 3 Alkynyl, and C 2 Alkynyl is included. 2 -C 6 Alkynyl includes the C 2 -C 5 All parts related to alkynyl and C 6 Alkynyl is included. 2 -C 10 Alkynyl includes the C 2 -C 5 Alkynyl and C 2 -C 6 All parts related to alkynyl and C 7 , C 8 , C 9 and C 10 Alkynyl is also included. 2 -C 12 Alkynyl includes all of the moieties listed above, as well as C 11 and C 12 Alkynyl is included. 2 -C 12 Non-limiting examples of alkenyls include ethynyl, propynyl, butynyl, pentynyl, etc. Unless stated otherwise in the specification, an alkyl group may be optionally substituted.

[0029] "Alkynylene" or "alkynylene chain" refers to an unsaturated, linear or branched divalent hydrocarbon chain radical having one or more alkynes and 2 to 12 carbon atoms. 2 -C 12 Non-limiting examples of alkynylene include ethynylene, propynylene, n-butynylene, etc. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group (e.g., as described herein) through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through any two carbons in the chain with appropriate valences. Unless stated otherwise in this specification, the alkynylene chain can be optionally substituted.

[0030] "Alkoxy" means a group of the formula -OR a In the formula, R a is an alkyl, alkenyl, or alkynyl as defined above containing 1 to 12 carbon atoms. Unless stated otherwise in the specification, an alkoxy group may be optionally substituted.

[0031] "Aryl" refers to a hydrocarbon ring system containing hydrogen, 6-18 carbon atoms and at least one aromatic ring, attached to the remainder of the molecule by a single bond. For purposes of this disclosure, the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl includes, but is not limited to, aryl derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene and triphenylene. Unless otherwise specified herein, "aryl" can be optionally substituted.

[0032] An "aralkyl" or "arylalkyl" is a group of the formula -R b -R c where R bis an alkylene group as defined above, R c is one or more aryl radicals as defined above, e.g., benzyl, diphenylmethyl, etc. Unless stated otherwise in the specification, an aralkyl group may be optionally substituted.

[0033] "Carbocyclyl", "carbocyclic ring" or "carbocycle" refers to a ring structure in which the atoms forming the ring are each carbon and are attached to the remainder of the molecule by a single bond. Carbocyclic rings can contain from 3 to 20 carbon atoms in the ring. Carbocyclic rings include aryl and cycloalkyl, cycloalkenyl, and cycloalkynyl as defined herein. Unless otherwise specified herein, carbocyclyl groups can be optionally substituted.

[0034] "Cycloalkyl" refers to a stable non-aromatic, monocyclic or polycyclic, fully saturated hydrocarbon, consisting solely of carbon and hydrogen atoms, which may include fused, bridged, or spirocyclic ring systems, having from 3 to 20 carbon atoms (e.g., having from 3 to 10 carbon atoms), and attached to the remainder of the molecule by a single bond. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated in the specification, cycloalkyl groups may be optionally substituted.

[0035] "Cycloalkenyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon consisting only of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which may include fused or bridged ring systems, having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, and attached to the remainder of the molecule by a single bond. Examples of monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like. Examples of polycyclic cycloalkenyls include bicyclo[2.2.1]hept-2-enyl, and the like. Unless otherwise specified herein, cycloalkenyl groups may be optionally substituted.

[0036] "Cycloalkynyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon consisting only of carbon and hydrogen atoms, containing one or more carbon-carbon triple bonds, which may include fused or bridged ring systems, having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, and attached to the remainder of the molecule by a single bond. Examples of monocyclic cycloalkynyl include cycloheptynyl, cyclooctynyl, and the like. Unless otherwise specified in this specification, cycloalkynyl groups may be optionally substituted.

[0037] "Haloalkyl" refers to an alkyl as defined above substituted by one or more halo radicals, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc. Unless stated otherwise in the specification, a haloalkyl group may be optionally substituted.

[0038] "Heterocyclyl", "heterocyclic ring" or "heterocycle" refers to a stable saturated, unsaturated, or aromatic 3-20 membered ring, consisting of 2-19 carbon atoms and 1-6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, attached to the remainder of the molecule by a single bond. Heterocyclyl or heterocyclic rings include heteroaryl, heterocyclylalkyl, heterocyclylalkenyl, and heterocyclylalkynyl. Unless otherwise stated herein, a heterocyclyl can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system and can include fused, bridged, and spirocyclic ring systems, the nitrogen, carbon, or sulfur atoms of the heterocyclyl can be optionally oxidized, the nitrogen atom can be optionally quaternized, and the heterocyclyl can be partially or fully saturated. Examples of such heterocyclyls include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise in the specification, heterocyclic groups may be optionally substituted.

[0039] "Heteroaryl" refers to a 5-20 membered ring system consisting of a hydrogen atom, 1-19 carbon atoms, 1-6 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, including compounds having aromatic resonance structures (e.g., 2-pyridones), and attached to the remainder of the molecule by a single bond. For purposes of this disclosure, a heteroaryl can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system and can include fused or bridged ring systems, and the nitrogen, carbon, or sulfur atoms of a heteroaryl can be optionally oxidized and the nitrogen atom can be optionally quaternized. Examples include azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl ... These include, but are not limited to, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise in the specification, a heteroaryl group may be optionally substituted.

[0040] "Heterocyclylalkyl" refers to a group of the formula -R b -R e where R b is an alkylene, alkenylene, or alkynylene group as defined above; R e is a heterocyclyl radical as defined above. Unless stated otherwise in the specification, a heterocyclylalkyl group may be optionally substituted.

[0041] The term "substituted" as used herein means that in any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, heterocyclyl, and / or heteroaryl), at least one hydrogen atom is replaced by a bond to a non-hydrogen atom, for example, but not limited to, a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl, alkoxy, and ester groups; a sulfur atom in groups such as thiol, thioalkyl, sulfone, sulfonyl, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, and triarylsilyl groups; and other heteroatoms in various other groups. "Substituted" also means that in any of the above groups, one or more hydrogen atoms are replaced by a heteroatom, such as the oxygen of oxo, carbonyl, carboxy, and ester groups, and a higher order bond (e.g., a double or triple bond) to the nitrogen of groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes the replacement of one or more hydrogen atoms in any of the above groups with -NR g R h , -NR g C(=O)R h , -NR g C(=O)NRg R h , -NR g C(=O)OR h , -NR g SO 2 R h , -OC(=O)NR g R h , -OR g , -SR g , -SOR g , -SO 2 R g , -OSO 2 R g , -SO 2 OR g , =NSO 2 R g , and -SO 2 NR g R h "Substituted" also includes replacing one or more hydrogen atoms in any of the above groups with -C(=O)R. g , -C(=O)OR g , -C(=O)NR g R h , -CH 2 SO 2 R g , -CH 2 SO 2 NR g R h In the above, R g and R hare the same or different and are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl, and / or heteroarylalkyl. "Substituted" further means that in any of the above groups, one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl group, and / or heteroarylalkyl group. In some embodiments, "substituted" further means that in any alkyl, cycloalkyl, or heterocyclylalkyl, one or more hydrogen atoms are replaced with an isotope, such as deuterium. Additionally, each of the aforementioned substituents may be optionally substituted with one or more of the substituents described above.

[0042] As used herein, the symbols [ka] (hereinafter sometimes referred to as "bond point") denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the bond point and the other of which is not depicted as being attached to the bond point. For example, [ka] indicates that the chemical entity "XY" is attached to another chemical entity through said attachment point. Furthermore, specific attachment points for chemical entities not depicted may be specified by inference. For example, R 3 is H or [ka] Compound CH where 3 -R 3 is R 3 When "XY" is selected, the attachment point is R 3 CH 3 It is to be inferred that the bond is the same as the bond depicted as being attached to

[0043] compound The present disclosure provides compounds that are agonists of the orexin type 2 receptor, and pharmaceutical compositions thereof, and their uses in the treatment of various diseases and disorders.

[0044] In embodiments, the present disclosure provides a compound of formula (I): [ka] or a pharma- ceutical acceptable salt or N-oxide thereof, During the ceremony, A is heteroaryl; L 1 -O-, -CR 5 R 6 - or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, Y is cycloalkyl, heterocyclyl, heteroaryl or aryl; Z is absent, heteroaryl or aryl; L 1 But, bond or CR 5 R 6 where Z is heteroaryl or aryl, the compound is [ka] Provided that:

[0045] In some embodiments, the present disclosure provides a compound of formula (I): [ka] or a pharma- ceutical acceptable salt thereof, During the ceremony, A is heteroaryl; L 1 -O-, -CR 5 R 6 - or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, Y is cycloalkyl, heterocyclyl, heteroaryl or aryl; Z is absent, heteroaryl or aryl; L 1 But, bond or CR 5 R 6where Z is heteroaryl or aryl, the compound is [ka] Provided that:

[0046] In some embodiments, the present disclosure provides a compound of formula (IA) [ka] or a pharma- ceutical acceptable salt thereof, wherein o, A, L 1 , L 2 , R 1 , R 2 , R 3 , R 4 , and R B is defined herein.

[0047] In some embodiments, the present disclosure provides a compound of formula (IA) [ka] or a pharma- ceutical acceptable salt thereof, A is heteroaryl; L 1 -O-, -CR 5 R 6 - or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, R B is independently selected for each occurrence from hydroxy, halo, -NO 2 , -CN, -NR 7 R 8 , -CO 2 R 10 , -OC(O)R 10 , -COR 10 , -C(O)NR 7 R 8 , -NR 7 C(O)R 10 , -OC(O)NR 7 R 8 , -NR 7 C(O)OR 10 , -S(O) w R 10 (where w is 0, 1, or 2), -OSO 2 R 10 , -SO 3 R 10 , -S(O) 2 NR 7 R 8 , -NR 7 S(O)2 R 10 , -NR 7 C(O)NR 7 R 8 , -C 1-6 Alkyl-NR 7 R 8 , -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, and C 2-6 alkynyl, R 10 are independently, for each occurrence, hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 selected from the group consisting of alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl; o is 0, 1, 2, 3, 4, or 5.

[0048] In some embodiments, the present disclosure provides a compound of formula (IAI) [ka] or a pharma- ceutical acceptable salt thereof, wherein o, A, L 1 , L 2 , R 1 , R 2 , R 3 , R 4 , and R B is defined herein.

[0049] In some embodiments, the present disclosure provides a compound of formula (IAI) [ka] or a pharma- ceutical acceptable salt thereof, A is heteroaryl; L 1 -O-, -CR 5 R 6- or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, R B is independently selected for each occurrence from hydroxy, halo, -NO 2 , -CN, -NR 7 R 8 , -CO 2 R 10 , -OC(O)R 10 , -COR 10 , -C(O)NR 7 R 8, -NR 7 C(O)R 10 , -OC(O)NR 7 R 8 , -NR 7 C(O)OR 10 , -S(O) w R 10 (where w is 0, 1, or 2), -OSO 2 R 10 , -SO 3 R 10 , -S(O) 2 NR 7 R 8 , -NR 7 S(O) 2 R 10 , -NR 7 C(O)NR 7 R 8 , -C 1-6 Alkyl-NR 7 R 8 , -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, and C 2-6 alkynyl, R 10 are independently, for each occurrence, hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 selected from the group consisting of alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl; o is 0, 1, 2, 3, 4, or 5.

[0050] In some embodiments, the present disclosure provides a compound of formula (IB): [ka] or a pharma- ceutical acceptable salt thereof, wherein o, q, A, L 2 , R 1 , R 2 , R 3 , R 4 , R A , and RB is defined herein.

[0051] In some embodiments, the present disclosure provides a compound of formula (IB): [ka] or a pharma- ceutical acceptable salt thereof, A is heteroaryl; L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8form a heterocycle together with the atoms to which they are attached, R A and R B is independently selected for each occurrence from hydroxy, halo, -NO 2 , -CN, -NR 7 R 8 , -CO 2 R 10 , -OC(O)R 10 , -COR 10 , -C(O)NR 7 R 8 , -NR 7 C(O)R 10 , -OC(O)NR 7 R 8 , -NR 7 C(O)OR 10 , -S(O) w R 10 (where w is 0, 1, or 2), -OSO 2 R 10 , -SO 3 R 10 , -S(O) 2 NR 7 R 8 , -NR 7 S(O) 2 R 10 , -NR 7 C(O)NR 7 R 8 , -C 1-6 Alkyl-NR 7 R 8 , -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, and C 2-6 alkynyl, R 10 are independently, for each occurrence, hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 selected from the group consisting of alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl; q is 0, 1, 2, 3, or 4; o is 0, 1, 2, 3, 4, or 5.

[0052] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is heteroaryl.

[0053] In some embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is a substituted or unsubstituted heteroaryl containing at least one nitrogen atom. In some embodiments, A contains one nitrogen atom. In some embodiments, A contains two nitrogen atoms.

[0054] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is a substituted or unsubstituted monocyclic or bicyclic nitrogen-containing heteroaryl.

[0055] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is selected from the group consisting of: [ka]

[0056] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is selected from the group consisting of: [ka]

[0057] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is [ka] In some embodiments, A is [ka] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is [ka] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is [ka] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is [ka] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is [ka] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is [ka] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is [ka] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is [ka] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is [ka] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is [ka] It is.

[0058] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 11 is alkyl optionally substituted with cyano, haloalkyl, cycloalkyl, or heterocyclyl.

[0059] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 11 is alkyl optionally substituted with cyano. In embodiments, R 11 is haloalkyl. In embodiments, R 11 is C 3-6 In embodiments, R 11 is heterocyclyl.

[0060] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 11 is alkyl, cycloalkyl or heterocyclyl.

[0061] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 11 is alkyl or haloalkyl.

[0062] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 11 is substituted alkyl. In some embodiments, R 11 is unsubstituted alkyl. In some embodiments, R 11 is alkyl optionally substituted with one or more deuterium atoms.

[0063] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 11 is methyl, -CH 2 CN, cyclopropyl, -CH 2 CF 2 H, or -CF 2 It's H.

[0064] In some embodiments of compounds of Formula (I), (IA), (IAI), and (IB), n is an integer from 0 to 6 (i.e., 0, 1, 2, 3, 4, 5, or 6). In some embodiments, n is an integer from 0 to 4, or 1 to 4. In some embodiments, n is an integer from 0 to 3, or 1 to 3. In embodiments, n is 0, 1, or 2. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.

[0065] In some embodiments of compounds of Formula (I), (IA), (IAI), and (IB), A is optionally one or more of R 9 In some embodiments, A is substituted with R 9 In some embodiments, A is unsubstituted.

[0066] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9 is independently at each occurrence hydrogen, alkyl, halogen, cyano, alkoxy, cycloalkyl, heterocyclyl, or heteroaryl. 9 is alkyl optionally substituted with one or more deuterium atoms.

[0067] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9is independently at each occurrence alkyl, halogen, cyano, alkoxy, or heteroaryl.

[0068] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9 independently, for each occurrence, -CH 3 , -OCH 3 , -CH 2 CH 3 , -CF 3 , -OCHF 2 , -Br, -Cl, -F, cyano, pyridinyl, or pyrazolyl.

[0069] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9 is independently at each occurrence hydrogen, alkyl, halogen, cyano, or alkoxy.

[0070] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9 is independently at each occurrence alkyl, halogen, cyano, or alkoxy. 9 is alkyl or halogen.

[0071] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9 independently, for each occurrence, C 1-3 Alkyl, C 1-3 Alkoxy, -Br, -Cl, -F, and cyano. In some embodiments, C 1-3 Alkyl and C 1-3 The alkoxy is optionally substituted with one or more -F.

[0072] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 9 independently, for each occurrence, -CH 3 , -OCH 3 , -CH 2CH 3 , -CF 3 , -OCHF 2 , -Br, -Cl, -F, or cyano.

[0073] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), n is 2 and R 9 is independently 1-3 In some embodiments, R 9 is unsubstituted C 1-3 In some embodiments, R 9 is methyl. In some embodiments, R 9 is -Cl.

[0074] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), A is selected from the group consisting of: [ka] Here, n is an integer from 0 to 6, R 9 is hydrogen, alkyl, haloalkyl, haloalkoxy, halogen, cyano, alkoxy, cycloalkyl, heterocyclyl, or heteroaryl; R 11 is alkyl optionally substituted with cyano, haloalkyl, cycloalkyl, or heterocyclyl.

[0075] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), A is selected from the group consisting of: [ka] Here, n is an integer from 0 to 6, R 9 is hydrogen, alkyl, halogen, cyano, alkoxy, cycloalkyl, heterocyclyl, or heteroaryl; R11 is alkyl, cycloalkyl or heterocyclyl.

[0076] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), n is 1 and R 9 is -CH 3 , -OCH 3 , -CH 2 CH 3 , -CF 3 , -OCHF 2 , -Br, -Cl, -F, or cyano. In some embodiments, n is 2 and R 9 are independently heteroaryl, -CH 3 Or halo.

[0077] In some embodiments of the compounds of Formula (I), (IA), and (IAI), L 1 -O-, -CR 5 R 6 - or a bond. In some embodiments, L 1 In some embodiments, L 1 is a bond. In some embodiments, L 1 -CR 5 R 6 -It is.

[0078] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), L 2 -CR 5 R 6 It is.

[0079] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 together with the atoms to which they are attached form a heterocycle.

[0080] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 It is.

[0081] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 1 is alkyl, haloalkyl, cycloalkyl, alkylene-alkoxy, or -NR 7 R 8 It is.

[0082] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 1 is methyl, -N(CH 3 ) 2 , cyclopropyl, -CH 2 CF 2 H, -CH 2 CF 3 , -CH 2 CH 2 F, or -CH 2 CH 2 OMe.

[0083] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 1 is alkyl, haloalkyl, or -NR 7 R 8 It is.

[0084] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 1 is alkyl or -NR 7 R 8 It is.

[0085] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 1 is alkyl.

[0086] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 1 is methyl.

[0087] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 1 -NR 7 R 8 It is.

[0088] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, halogen, or R 2 and R 3 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring.

[0089] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 2 , R 3 , R 4 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen.

[0090] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 2 , R 3 , R 4 is independently alkyl or hydrogen.

[0091] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 2 and R 3 are independently hydrogen or alkyl; R 4 is hydrogen.

[0092] In embodiments of the compounds of formula (I), (IA), (IAI), and (IB), R 2 and R 3 are independently hydrogen or methyl; R 4 is hydrogen.

[0093] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 2 , R 3 , R 4 At least one of is alkyl.

[0094] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 2 , R 3 , R 4 At least two of are alkyl.

[0095] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 2 , R 3 , R 4 is hydrogen.

[0096] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 together with the atoms to which they are attached form a carbocyclic or heterocyclic ring.

[0097] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen.

[0098] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 5 and R 6 is hydrogen.

[0099] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 together with the atoms to which they are attached form a heterocycle.

[0100] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 7 and R 8 is independently hydrogen, alkyl, cycloalkyl, or heterocyclyl.

[0101] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 7 and R 8 is alkyl.

[0102] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 7 and R 8 -CH 3 It is.

[0103] In some embodiments of the compounds of Formula (I), Y is cycloalkyl, heterocyclyl, heteroaryl, or aryl.

[0104] In some embodiments of the compounds of Formula (I), Y is cycloalkyl or aryl.

[0105] In some embodiments of the compound of Formula (I), Y is a 3-7 membered monocyclic cycloalkyl, a 5-8 membered bicyclic cycloalkyl, a 4-7 membered saturated heterocyclyl, a 5-8 membered bicyclic heterocyclyl, a 5-6 membered heteroaryl, or phenyl, in embodiments, the 5-10 membered heteroaryl or phenyl is substituted with one or more halogens.

[0106] In some embodiments of the compounds of Formula (I), Y is a 3-7 membered monocyclic cycloalkyl.

[0107] In some embodiments of the compounds of Formula (I), Y is a 6-membered monocyclic cycloalkyl.

[0108] In some embodiments of the compounds of Formula (I), Y is unsubstituted cyclohexyl.

[0109] In some embodiments of the compounds of Formula (I), Y is optionally selected from one or more R A In some embodiments, Y is optionally substituted with 1, 2, 3, or 4 R A is replaced by.

[0110] In an embodiment of the compound of Formula (I), Y is 2-oxaspiro[4.5]decane or cyclohexyl, optionally substituted with one or more alkyl or cycloalkyl.

[0111] In an embodiment of the compound of Formula (I), Y is optionally C 1-3 2-oxaspiro[4.5]decane or cyclohexyl substituted with alkyl or cyclopropyl.

[0112] In some embodiments of the compounds of Formula (I), Y is phenyl.

[0113] In some embodiments of the compounds of Formula (I), Y is optionally substituted with one or more deuterium.

[0114] In some embodiments of the compounds of Formula (I), Z is absent, heteroaryl or aryl, while L 1 is a bond or CR 5 R 6 In the case of, Z is heteroaryl or aryl.

[0115] In some embodiments of the compounds of Formula (I), Z is heteroaryl or aryl.

[0116] In some embodiments of the compounds of Formula (I), Z is heteroaryl.

[0117] In some embodiments of the compounds of Formula (I), Z is aryl.

[0118] In some embodiments of the compounds of Formula (I), Z is absent.

[0119] In some embodiments of the compounds of Formula (I), Z is a 5-10 membered heteroaryl or phenyl.

[0120] In some embodiments of the compounds of Formula (I), Z is phenyl.

[0121] In some embodiments of the compound of formula (I), Z is unsubstituted phenyl. In some embodiments, Z is phenyl substituted with one or more fluoro. In some embodiments, Z is phenyl substituted with one or two halogens.

[0122] In embodiments of the compounds of Formula (I), Z may optionally be one or more of R B In embodiments, Z is optionally substituted with 1, 2, 3, 4, or 5 R B is replaced by.

[0123] In some embodiments of the compounds of Formula (I), Y and Z are phenyl.

[0124] In some embodiments of the compounds of Formula (I), Y is cyclohexyl and Z is phenyl.

[0125] In some embodiments of the compounds of Formula (I), Y and Z together are: [ka] It is.

[0126] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R A and R B is independently selected for each occurrence from hydroxy, halo, -NO 2 , -CN, -NR 7 R 8 , -CO 2 R 10 , -OC(O)R 10 , -COR 10 , -C(O)NR 7 R 8 , -NR 7 C(O)R 10 , -OC(O)NR 7 R 8 , -NR 7 C(O)OR 10 , -S(O) w R 10 (where w is 0, 1, or 2), -OSO 2 R 10 , -SO 3 R 10 , -S(O) 2 NR 7 R 8 , -NR 7 S(O) 2 R 10 , -NR 7 C(O)NR 7 R 8 , -C 1-6 Alkyl-NR 7 R 8 , -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6Alkenyl, and C 2-6 alkynyl.

[0127] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R B is a halogen.

[0128] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R B is fluoro.

[0129] In some embodiments of compounds of Formula (I), (IA), (IAI), and (IB), o and q are each independently 0, 1, 2, 3, 4, or 5.

[0130] In some embodiments of compounds of Formula (I), (IA), (IAI), and (IB), o is 0 or 1. In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, o is 2. In some embodiments, o is 3. In some embodiments, o is 4. In some embodiments, o is 5.

[0131] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), o is 1 and R B is fluoro.

[0132] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), q is 0 or 1. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 5.

[0133] In some embodiments of the compounds of Formula (I), (IA), (IAI), and (IB), R 10are independently, for each occurrence, hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 It is selected from the group consisting of alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl.

[0134] In all embodiments of the present disclosure, the compound is: [ka] isn't it.

[0135] In some embodiments, the compounds described herein may also include one or more isotopic substitutions. Examples of isotopes suitable for incorporation into the compounds of the present disclosure include hydrogen isotopes, e.g., 2 H and 3 H, carbon isotopes, e.g. 11 C. 13 C and 14 C, nitrogen isotopes, e.g. 13 N and 15 N, oxygen isotopes, e.g. 18 O, phosphorus isotopes, e.g. 32 P, sulfur isotopes, e.g. 35 S, fluorine isotopes, e.g. 18 F, iodine isotopes, e.g. 123 I and 125 I, as well as chlorine isotopes, e.g. 36 Isotopically enriched compounds of the present disclosure may be prepared, for example, by conventional techniques known to those skilled in the art or by processes analogous to those described in the schemes and examples herein using appropriate isotopically enriched reagents and / or intermediates.

[0136] In some embodiments, the compounds disclosed herein are racemic mixtures. In some embodiments, the compounds disclosed herein are enriched in one enantiomer. In some embodiments, the enriched compounds disclosed herein are substantially free of the other enantiomer. In embodiments, the compounds disclosed herein are provided (+)-enantiomers. In embodiments, the compounds disclosed herein are provided (-)-enantiomers. In some embodiments, the compounds disclosed herein have an enantiomeric excess of about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, about 98.5% or more, about 99% or more, about 99.5% or more, or more, including all subranges and values ​​therebetween. In some embodiments, the compounds disclosed herein are provided as a mixture of diastereomers. In some embodiments, the diastereomers of the compounds disclosed herein are provided substantially free of other possible diastereomer(s). In embodiments, the disclosure includes tautomers of any of these compounds.

[0137] In some embodiments, provided herein is one or more compounds selected from Table 1, or a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof.

[0138] In some embodiments, provided herein is one or more compounds selected from Table 1, or a pharma- ceutically acceptable salt thereof, or an enantiomer thereof.

[0139] In some embodiments, provided herein is one or more compounds selected from Table 1 or a pharma- ceutically acceptable salt thereof, or a diastereomer thereof, or a mixture of diastereomers.

[0140] In embodiments, the compound of formula (I), (IA), (IAI), (IB), or Table 1 has the (R) configuration at the carbon marked with an asterisk (*): [ka]

[0141] In embodiments, the compound of formula (I), (IA), (IAI), (IB), or Table 1 has the (S) configuration at the carbon marked with an asterisk (*): [ka]

[0142] In an embodiment, a compound of formula (I), (IA), (IAI), (IB), or Table 1 has the (R) configuration at the carbon labeled with an asterisk (*). In an embodiment, a compound of formula (I), (IA), (IAI), (IB), or Table 1 has the (S) configuration at the carbon labeled with an asterisk (*). In an embodiment, a compound of formula (I), (IA), (IAI), (IB), or Table 1 has the (R) configuration at the carbon labeled with a double asterisk (**). In an embodiment, a compound of formula (I), (IA), (IAI), (IB), or Table 1 has the (S) configuration at the carbon labeled with a double asterisk (**): [ka]

[0143] In some embodiments, provided herein is one or more compounds selected from Table 1.

[0144] In some embodiments, provided herein are one or more pharma- ceutically acceptable salts of a compound selected from Table 1. [Table 1-1]

Table 1-2

Table 1-3

Table 1-4

Table 1-5

Table 1-6

Table 1-7

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

[0145] composition The present disclosure provides pharmaceutical compositions for modulating an orexin receptor (e.g., an orexin type 2 receptor) in a subject. In some embodiments, the pharmaceutical compositions comprise one or more compounds of the present disclosure (e.g., a compound of formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions comprise one or more compounds of the present disclosure (e.g., a compound of formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt or N-oxide thereof.

[0146] In some embodiments of the disclosure, the pharmaceutical compositions comprise a therapeutically effective amount of one or more compounds of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

[0147] In some embodiments, the pharmaceutical composition comprises one or more compounds selected from Table 1 or a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof, as described herein.

[0148] In some embodiments, the pharmaceutical composition comprises one or more compounds selected from Table 1, or a pharma- ceutically acceptable salt thereof, as described herein.

[0149] In some embodiments of the present disclosure, a pharmaceutical composition is provided that includes one or more compounds of the present disclosure (e.g., compounds of formula (I), (IA), (IAI), (IB), or Table 1) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient or adjuvant. The pharma- ceutically acceptable excipient and adjuvant are added to the composition or formulation for various purposes. In some embodiments, a pharmaceutical composition that includes one or more compounds disclosed herein, or a pharma- ceutical acceptable salt thereof, further includes a pharma- ceutical acceptable carrier. In some embodiments, the pharma- ceutical acceptable carrier includes a pharma- ceutical acceptable excipient, binder, and / or diluent. In some embodiments, suitable pharma- ceutical acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions. In some embodiments, suitable pharma- ceutical acceptable excipients include, but are not limited to, water, saline, alcohol, polyethylene glycol, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.

[0150] For the purposes of this disclosure, the compounds of this disclosure can be formulated into formulations containing pharma- ceutically acceptable carriers, adjuvants and vehicles for administration by various means, including oral, parenteral, by inhalation spray, topical, or rectal.As used herein, the term parenteral includes subcutaneous, intravenous, intramuscular, and intraarterial injections by various infusion techniques.As used herein, intraarterial and intravenous injections include administration via catheter.

[0151] In general, the compounds of the present disclosure are administered in a therapeutically effective amount. The amount of compound actually administered will usually be determined by the physician in light of the relevant circumstances, including the condition being treated, the selected route of administration, the actual compound being administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0152] Treatment method The compounds of the present disclosure are used in many ways. For example, in some embodiments, the compounds are useful in methods for modulating orexin receptors, such as orexin type 2 receptors. Thus, in some embodiments, the present disclosure provides the use of any one of the compounds of formula (I), (IA), (IAI), (IB), or Table 1 above, or a pharma- ceutically acceptable salt thereof, for modulating orexin receptor (e.g., orexin type 2 receptor) activity. For example, in some embodiments, the modulation of orexin receptor (e.g., orexin type 2 receptor) activity is in mammalian cells. The modulation of orexin receptor (e.g., orexin type 2 receptor) activity is for the treatment of any of the above conditions or diseases in a subject in need thereof (e.g., a mammalian subject, e.g., a human).

[0153] In some embodiments, modulating the activity of an orexin receptor (e.g., an orexin type 2 receptor) is binding. In some embodiments, modulating the activity of an orexin receptor (e.g., an orexin type 2 receptor) is agonizing or stimulating the orexin receptor.

[0154] In some embodiments, the disclosure provides a method of treating a disease or disorder treatable by administration of an orexin agonist, the method comprising administering a therapeutically effective amount of one or more compounds of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutical acceptable salt thereof.

[0155] In some embodiments, compounds of the disclosure are used to treat, prevent, ameliorate, control, or reduce the risk of various disorders associated with orexin receptors, including one or more of the following conditions or diseases: narcolepsy, narcolepsy syndrome with narcolepsy-like symptoms, cataplexy in narcolepsy, excessive daytime sleepiness in narcolepsy (EDS), hypersomnia, idiopathic hypersomnia, recurrent hypersomnia, endogenous hypersomnia, hypersomnia with daytime hypersomnia, wakefulness during the night, sleep apnea, hypersomnia with sleep apnea, nocturnal myoclonus, disturbances of consciousness, e.g., coma, REM sleep interruptions, jet lag, excessive daytime sleepiness, shift work sleep disorder, sleep parasomnia, sleep disorder ... hypersomnia associated with depression, affective / mood disorders, substance use, Alzheimer's disease or cognitive disorders, Parkinson's disease, Guillain-Barre syndrome, Kleine-Lewin syndrome, and conditions associated with sleep disorders associated with aging, muscular dystrophies, immune-mediated diseases, Alzheimer's sundowning, circadian rhythms associated with time zone travel and shift work schedules, and mental and physical disorders, fibromyalgia, heart failure, diseases associated with bone loss, sepsis, syndromes characterized by nonrestorative sleep and muscle pain or sleep apnea with disturbed breathing during sleep, conditions resulting from poor quality sleep, and other diseases associated with general orexin system dysfunction. In some embodiments, compounds of the disclosure are useful for treating, preventing, ameliorating, controlling, or reducing the risk of side effects and complications due to various conditions including narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy with narcolepsy-like symptoms, hypersomnia with excessive daytime sleepiness (e.g., Parkinson's disease, Guillain-Barré syndrome, and Kleine-Lewin syndrome), Alzheimer's, obesity, insulin resistance syndrome, heart failure, diseases associated with bone loss, sepsis, disorders of consciousness such as coma, anesthesia, or the like, or anesthetic antagonists.

[0156] In some embodiments, a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, is used to treat a disease or disorder or condition associated with excessive sleepiness in a subject in need of such treatment. In some embodiments, the excessive sleepiness is caused by any one of the following: a lack of quality or quantity of nighttime sleep, a misalignment of the body's circadian pacemaker due to the environment (e.g., caused by the need to remain awake at night due to work, e.g., shift work, or personal reasons, e.g., caring for an ill, minor, or elderly family member), e.g., jet lag, shift work, and other circadian rhythm sleep disorders, another underlying sleep disorder, e.g., narcolepsy (e.g., narcolepsy type 1, narcolepsy type 2, probable narcolepsy), sleep apnea (e.g., obstructive sleep apnea, obstructive sleep apnea using continuous positive airway pressure), idiopathic hypersomnia, idiopathic excessive sleepiness, and restless legs syndrome, clinical or atypical depression, tumors, head trauma, anemia, renal failure, hypothyroidism, central nervous system injury, drug abuse, genetic vitamin deficiencies, e.g., biotin deficiency, and certain classes of prescription and over-the-counter medications.

[0157] In some embodiments, a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, is used to treat any one of the following: shift work disorder, shift work sleep disorder, and jet lag. In some embodiments, the methods and uses herein are used to treat any one of the following: narcolepsy type 1, narcolepsy type 2, probable narcolepsy, idiopathic hypersomnia, idiopathic excessive sleepiness, hypersomnia, hypersomnolence, sleep apnea syndrome (e.g., obstructive sleep apnea, obstructive sleep apnea using continuous positive airway pressure), or disturbances in consciousness such as coma, and narcolepsy syndrome with narcolepsy-like symptoms, hypersomnolence or hypersomnia with excessive daytime sleepiness (e.g., Parkinson's disease ... Narcolepsy (e.g., narcolepsy type 1, narcolepsy type 2, probable narcolepsy) can be diagnosed by diagnostic criteria commonly used in the art, such as the International Classification of Sleep Disorders, Third Edition (ICSD-3) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). In some embodiments, the excessive sleepiness is excessive daytime sleepiness or excessive sleepiness during working hours, or excessive sleepiness or poor quality of sleep caused by the need to remain awake at night for work (e.g., shift work) or personal reasons (e.g., taking care of sick, minor or elderly family members).In some embodiments, the subject suffers from a disease or disorder or condition that is accompanied by excessive sleepiness.In some embodiments, the subject is a sleep-deprived subject, a subject with excessive sleepiness, a subject with a disrupted regular sleep cycle, or a subject who needs to reduce sleepiness.In some embodiments, the present disclosure provides a method for reducing or treating excessive sleepiness. In some embodiments, the excessive sleepiness is caused by narcolepsy type 1, narcolepsy type 2 or idiopathic hypersomnia. In some embodiments, the excessive sleepiness is caused by obstructive sleep apnea despite the use of continuous positive airway pressure (CPAP). In some embodiments, a method for increasing wakefulness in a subject who needs to do so is provided. In some embodiments, the orexin level in the subject is not impaired or partially impaired.

[0158] In some embodiments of the disclosure, there is provided a method of treating a sleep disorder (e.g., those disclosed herein) in a subject in need thereof, the method comprising administering a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, to a subject in need thereof. In some embodiments, a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, is used to treat a subject having a sleep disorder, to treat a sleep disorder, or to treat a symptom of a sleep disorder.

[0159] In some embodiments of the disclosure, there is provided a method of treating narcolepsy in a subject in need thereof, the method comprising administering a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, to a subject in need thereof. In some embodiments, a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, is used to treat a subject with narcolepsy, to treat narcolepsy, or to treat the symptoms of narcolepsy.

[0160] In some embodiments of the disclosure, there is provided a method of treating idiopathic hypersomnia (IH) in a subject in need thereof, the method comprising administering a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, to a subject in need thereof. In some embodiments, a compound of the disclosure (e.g., a compound of Formula (I), (IA), (IAI), (IB), or Table 1), or a pharma- ceutically acceptable salt thereof, is used to treat a subject with IH, to treat IH, or to treat the symptoms of IH. EXAMPLES

[0161] Having now generally described the disclosure, it will be more readily understood by reference to the following examples, which are included solely for the purpose of illustrating certain aspects and embodiments of the disclosure and are not intended to limit the disclosure.

[0162] The compounds of the present disclosure can be synthesized using the methods described below, as well as synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those of skill in the art.

[0163] Preparation of compounds can involve protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one of ordinary skill in the art. The chemistry of protecting groups can be found, for example, in Greene and Wuts, Protective Groups in Organic Synthesis, 44th. Ed., Wiley & Sons, 2006, and Jerry March, Advanced Organic Chemistry, 4 th edition, John Wiley & Sons, publisher, New York, 1992.

[0164] IP-1 accumulation assay Inositol-1 monophosphate (IP-1) accumulation was measured in human recombinant OX1 (hOX1) and OX2 (hOX2) receptors expressed in CHO cells (DiscoverX) using the IP-On HTRF® terbium cryptate-based assay (Cisbio) according to the manufacturer's instructions for cells examined in suspension.

[0165] hOX1-CHO and hOX2-CHO cells were seeded in white 384-well plates at a density of 20,000 cells / well in Hanks' Balanced Salt Solution (HBSS) containing 20 mM HEPES pH 7.4, 50 mM LiCl and 0.1% bovine serum albumin (BSA).

[0166] Compounds of the present disclosure were tested in an 11-point concentration response curve (CRC) in 200-fold serial dilutions in pure DMSO and added to cells by echoacoustic liquid processing method (Labocyte) (final DMSO in the assay 0.5%). After 60 minutes of incubation at 37°C, the detection reagents IP1-d2 tracer and anti-IP1-cryptate were diluted in lysis buffer according to the manufacturer's instructions and added to the cells.

[0167] After 60 min of incubation at room temperature, time resolved fluorescence (HTRF) was measured at 615 nm and 665 nm by an Envision Multilabel reader (Perkin Elmer) and the HTRF ratio (A665 / A615x104) was calculated.

[0168] IP-1 accumulation responses were expressed as a percentage of the maximum OX-A response.

[0169] Curve fitting and EC50 estimation was performed using a four-parameter logistic model using XLfit software. EC50 mean data are calculated from at least two independent experiments performed in duplicate.

[0170] In the table, Category A corresponds to compounds exhibiting an IC50 of less than 100 nM, Category B corresponds to compounds exhibiting an IC50 of 100 nM to 1,000 nM, Category C corresponds to compounds exhibiting an IC50 of 1,000 nM to 10,000 nM, and Category D corresponds to compounds exhibiting an IC50 of more than 10,000 nM.

[0171] Example 1: N-[2-(2-oxo-1,2-dihydropyridin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (1) [ka] Methyl (2E)-3-{[(CIS)-4-phenylcyclohexyl]oxy}prop-2-enoate (Intermediate 1) [ka]

[0172] cis-4-Phenylcyclohexan-1-ol (2.04 g, 11.57 mmol) and DABCO (0.13 g, 1.16 mmol) were stirred in DCM (45 mL) at 0° C. while 2-propynoic acid methyl ester (1.34 mL, 15.05 mmol) was added dropwise over 5 min. The solution was stirred at room temperature for 30 min. The solvent was removed in vacuo and the residue was purified by column chromatography (H) using a C18 cartridge. 2 HO+0.1% formic acid / MeCN+0.1% formic acid, 80:20 to 0:100) to give the title compound (2.31 g, 8.87 mmol, 77% yield) as an off-white solid. [M+H] + m / z 261.2

[0173] Methyl (2Z)-2-(2-oxo-1,2-dihydropyridin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}prop-2-enoate (Intermediate 2) [ka]

[0174] To a solution of methyl intermediate 1 (3.05 g, 11.72 mmol) in anhydrous THF (55 ml) at 0° C. was added a solution of pyridinium tribromide (3.93 g, 12.3 mmol) in THF (10 ml) over 10 min. The reaction mixture was warmed to room temperature and stirred for 30 min. 1H-Pyridin-2-one (2.79 g, 29.29 mmol) was added and the mixture was stirred at room temperature for 16 h. The solvent was removed in vacuo and the product was purified by column chromatography using a silica cartridge (0-100% EtOAc in cHex) to give the title compound (1.62 g, 4.58 mmol, 39% yield) as a colorless glassy solid. [M+H] + m / z354.2

[0175] 1-(1-Hydroxy-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 3) [ka]

[0176] To a solution of intermediate 2 (1.52 g, 4.3 mmol) in THF (50 mL) and MeOH (5 mL) was added NaBH 4 (814 mg, 21.5 mmol) was added. The mixture was heated at 80° C. and after 1 h, acetone was added at room temperature. The solvent was removed in vacuo and then H 2 0 and 1M aqueous HCl were added. The mixture was extracted with EtOAc, and the combined organic layers were then evaporated in vacuo to give the title compound (1.56 g, quantitative yield) as a white foam. [M+H] + m / z 328.2.

[0177] 1-(1-Azido-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 4) [ka]

[0178] To a solution of intermediate 3 (823 mg, 2.41 mmol) in THF (15 mL) at 0° C. was added TEA (0.5 mL, 3.62 mmol) and methanesulfonyl chloride (0.21 mL, 2.65 mmol). After 30 min, NaN 3 (29 mg, 0.440 mmol) was added at 0° C. The mixture was allowed to warm to room temperature and stirred overnight. After 18 h, the mixture was diluted with H 2 O and extracted twice with EtOAc. The combined organic layers were evaporated in vacuo to give the title compound (877 mg, quantitative yield) as a pale pink oil. [M+H] + m / z 353.2

[0179] 1-(1-amino-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 5) [ka]

[0180] To a stirred solution of intermediate 4 (0.88 g, 2.49 mmol) in THF (9 mL) was added PPh 3 (1.31 g, 4.98 mmol) and H 2 2H2O (4 mL) was added. After the mixture was stirred at room temperature for 4 h, it was diluted with water and extracted twice with EtOAc. The combined organic layers were evaporated in vacuo. The product was purified using an SCX cartridge (loaded with MeOH, washed with MeOH, and washed with 2M NH 3 in MeOH) to give a pink oil, which was further purified by column chromatography on a silica cartridge (0-5% methanol in DCM) to give the title compound (0.24 g, 0.74 mmol, 30% yield) as a pale yellow oil. [M+H] + m / z 327.5

[0181] N-[2-(2-oxo-1,2-dihydropyridin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (1) [ka]

[0182] To a stirred solution of intermediate 5 (15 mg, 0.050 mmol) in THF (0.6 mL) was added TEA (12.81 uL, 0.090 mmol) at room temperature followed by methanesulfonyl chloride (4 μL, 0.060 mmol). The mixture was stirred at room temperature and after 30 min the solvent was removed in vacuo. The product was purified by column chromatography using a C18 cartridge (H 2 3H O+0.1% formic acid / MeCN+0.1% formic acid, 95:5 to 40:60) to afford the title compound (12.8 mg, 0.032 mmol, 69% yield) as a white solid.

[0183] Examples 1a-1e: Examples 1a-1e in Table 2 below were prepared according to the procedure described in Example 1 using the appropriate heterocyclic reagents. These starting materials were either prepared as described in the intermediates section, commercially available, or could be prepared from commercially available reagents using conventional reactions well known in the art. The enantiomers were separated by chiral purification using appropriate columns, Chiralpak columns (AD-H, IC, OJ-H), eluting with mixtures n-hexane / EtOH, n-hexane / (EtOH+0.1% iPrNH2), n-hexane / (EtOH / MeOH 1:1+0.1% iPrNH2) in ratios of 35:65 to 70:30. During the chiral separation, using one of the conditions reported above, isomer 1 was assigned to the first eluting compound and isomer 2 to the second eluting compound. These products are reported in the table below: [Table 2-1] [Table 2-2] [Table 2-3]

[0184] Example 1f: 1-{1-[(dimethylsulfamoyl)amino]-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl}-1,2-dihydropyridin-2-one (1f) [ka] To a stirred solution of intermediate 5 (30 mg, 0.090 mmol) in THF (3.4 mL) was added TEA (26 μL, 0.18 mmol) at room temperature followed by N,N-dimethylsulfamoyl chloride (12 μL, 0.11 mmol). The mixture was stirred at 50° C. for 24 h. Additional N,N-dimethylsulfamoyl chloride (12 μL, 0.11 mmol) was added and the mixture was stirred at 50° C. for 20 h. The solvent was removed in vacuo. The product was purified by HPLC preparative chromatography to give the title compound (4.5 mg, 0.010 mmol, 11% yield) as a white solid. [Table 3]

[0185] Example 2: N-[2-(3-ethyl-2-oxo-1,2-dihydropyridin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide [ka] CIS-4-(prop-2-en-1-yloxy)cyclohexyl]benzene (Intermediate 6) [ka]

[0186] To a mixture of cis-4-phenylcyclohexan-1-ol (3.0 g, 17.02 mmol) in anhydrous THF (50 mL) was added NaH (0.89 g, 22.13 mmol) (60% w / w dispersion in mineral oil) at room temperature.2 After stirring at room temperature for 45 min under atmospheric conditions, allyl bromide (2.21 mL, 25.54 mmol) was added. The mixture was stirred at 60° C. for 5 h, after which it was poured onto ice and extracted with EtOAc (3×150 mL). The organic layer was diluted with Na 2 SO 4 The mixture was dried at 40° C. and evaporated in vacuo. The product was purified by column chromatography using a silica cartridge (cHex / EtOAc 100:0 to 70:30) to give the title compound (3.35 g, 15.49 mmol, 91% yield) as a pale yellow oil. 2 O] + m / z 159.0.

[0187] [CIS-4-{[(2E)-3-nitroprop-2-en-1-yl]oxy}cyclohexyl]benzene (Intermediate 7) [ka]

[0188] To a suspension of intermediate 6 (688 mg, 3.18 mmol) in anhydrous 1,4-dioxane (25 mL) stirred at room temperature under air, TEMPO (200 mg, 1.27 mmol) and tBuONO (0.76 mL, 6.36 mmol) were added. The mixture was stirred at 50° C. for 2.5 h, then diluted with EtOAc (100 mL) and saturated NH 4 The mixture was washed with aqueous Cl (2x40 mL). The organic layer was dried on a phase separator and concentrated in vacuo. The product was purified by column chromatography on a silica cartridge (0-15% EtOAc in cHex) and then on a C18 cartridge (H 2 Purification by column chromatography using 2H+0.1% formic acid / MeCN+0.1% formic acid 100:0 to 0:100) afforded the title compound (300 mg, 1.15 mmol, 36% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl 3) δ 7.39 - 7.28 (m, 4H), 7.25 - 7.17 (m, 3H), 4.27 (dd, J = 3.2, 2.0 Hz, 2H), 3.72 (t, J = 3.1 Hz, 1H), 2.56 (tt, J = 11.9, 3.7 Hz, 1H), 2.05 (dt, J = 14.7, 2.8 Hz, 2H), 1.89 - 1.76 (m, 2H), 1.72 - 1.55 (m, 4H).

[0189] 3-Ethyl-1-(1-nitro-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 8) [ka]

[0190] 3-Ethyl-1H-pyridin-2-one (188 mg, 1.53 mmol) and intermediate 7 (200 mg, 0.77 mmol) were dissolved in THF (14 mL). The solution was stirred at 80° C. for 39 h. The mixture was diluted with H 2 O and extracted with EtOAc. The organic layer was evaporated in vacuo to give the title compound (357 mg, quantitative yield) as a yellow oil. [M+H] + m / z 385.2.

[0191] 1-(1-amino-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-3-ethyl-1,2-dihydropyridin-2-one (Intermediate 9) [ka]

[0192] To a solution of intermediate 8 (350 mg, 0.91 mmol) in EtOH (8 mL) was added AcOH (1.3 mL) and Zn powder (595 mg, 9.1 mmol) and the mixture was stirred at room temperature for 45 min. The mixture was filtered through Celite and washed with MeOH. The filtrate was concentrated in vacuo and diluted with NaOH (2M H2 2H2O solution) was added. The mixture was extracted with EtOAc and the organic layer was evaporated in vacuo to give the crude which was further loaded into SCX (MeOH, washed with MeOH and purified with MeOH / NH 4 The solvent was removed in vacuo to give the title compound (202 mg, 0.57 mmol, 63% yield) as a yellow oil. [M+H] + m / z 356.6.

[0193] N-[2-(3-ethyl-2-oxo-1,2-dihydropyridin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (2) [ka]

[0194] Example 2 was prepared from Intermediate 9 (50 mg, 0.14 mmol) following the procedure described for Example 1 to afford the title compound (34 mg, 0.078 mmol, 55% yield) as a colorless glassy solid.

[0195] The following examples were prepared according to the same three-step procedure described for the synthesis of Example 2, using the corresponding commercially available starting materials that were either prepared as described in the intermediates section, were commercially available, or could be prepared from commercially available reagents using conventional reactions known in the art. Example 2aa was prepared according to the three-step procedure used for the synthesis of Example 2, with the only change being that in step 1, 3-methylpyrazole was reacted with intermediate 7 in DCM at room temperature. Examples 2af, 2ag, 2ah, and 2ai were prepared according to the same procedure described for the synthesis of Example 2, using F-phenylcyclohexanol.

[0196] The enantiomers were purified by chiral purification using Chiralpak columns (AD-H, IC, OJ-H) in the mixtures n-hexane / EtOH, n-hexane / (EtOH+0.1% iPrNH 2), n-Hexane / (EtOH / MeOH 1:1+0.1% iPrNH 2 ) in ratios ranging from 35:65 to 70:30. During the course of the chiral separation using one of the conditions reported above, isomer 1 was assigned to the first eluting compound and isomer 2 to the second eluting compound. These products are reported in the table below: [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8] [Table 4-9] [Table 4-10] [Table 4-11] [Table 4-12]

Table 4-13

Table 4-14

Table 4-15

Table 4-16

Table 4-17

Table 4-18

Table 4-19

Table 4-20

Table 4-21

Table 4-22

Table 4-23

Table 4-24

Table 4-25

Table 4-26

[0197] Example 2ak: N-[2-(2-oxo-1,2-dihydroquinolin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide [ka] 1-(1-nitro-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydroquinolin-2-one (Intermediate 10) [ka]

[0198] To a suspension of 2-hydroxyquinoline (111 mg, 0.77 mmol) in THF (2 mL) was added tBuOK (52 mg, 0.46 mmol) and 18-crown-6 (40 mg, 0.15 mmol) at 0° C. The reaction mixture was stirred at this temperature for 1 h and then cooled to −50° C. A solution of intermediate 7 (100 mg, 0.38 mmol) in THF (2 mL) was added and the reaction mixture was stirred at −50° C. for 15 min. The solution was diluted with H 2 O and extracted with EtOAc. The organic layer was evaporated in vacuo. The product was purified by column chromatography using a C18 cartridge (H 2 HO+0.1% formic acid / MeCN+0.1% formic acid, 95:5 to 0:100) to give the title compound (17 mg, 0.042 mmol, 11% yield). + m / z 407.3.

[0199] 1-(1-amino-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydroquinolin-2-one (Intermediate 11) [ka]

[0200] Intermediate 11 was prepared from intermediate 10 (17 mg, 0.042 mmol) following the procedure described for intermediate 9 to give the title compound (8 mg, 0.021 mmol, 64% yield) as a white solid. [M+H] + m / z 377.2.

[0201] N-[2-(2-oxo-1,2-dihydroquinolin-1-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (2ak) [ka]

[0202] Example 2ak was prepared from Intermediate 11 (7 mg, 0.020 mmol) following the procedure described for Example 1 to afford the title compound (1.4 mg, 0.003 mmol, 16% yield) as a white solid. [Table 5]

[0203] Examples 3a to 3d: N-[(2S,3S)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3a), N-[(2R,3R)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3b), N-[(2R,3S)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3c), and N-[(2S,3R)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3d) [ka] 2-{[(CIS)-4-phenylcyclohexyl]oxy}acetaldehyde (Intermediate 12) [ka]

[0204] Intermediate 6 (3.24 g, 14.98 mmol) in THF (34 mL) and H 2 In a mixture of K 2 OsO 4 2H 2 NaIO (276 mg, 0.75 mmol) was added. The mixture was stirred at room temperature for 3 h. 4 (9.61 g, 44.93 mmol) was added and the mixture was stirred at room temperature for 3 h. 2 The mixture was poured into O and extracted with EtOAc. The organic layer was washed with brine and concentrated in vacuo. The product was purified by column chromatography using a silica cartridge (cHex / EtOAc 100:0 to 20:80) to give the title compound (2.36 g, 10.81 mmol, 72% yield) as a yellow-green oil. 1 H NMR (400 MHz, CDCl 3) δ 9.81 (t, J = 1.1 Hz, 1H), 7.37 - 7.13 (m, 5H), 4.07 (d, J = 1.1 Hz, 2H), 3.71 (p, J = 3.0 Hz, 1H), 2.62 - 2.47 (m, 2H), 2.12 - 2.03 (m, 2H), 1.87 (qd, J = 13.0, 3.4 Hz, 2H), 1.72 - 1.55 (m, 3H).

[0205] [CIS-4-{[-3-nitrobut-2-en-1-yl]oxy}cyclohexyl]benzene (Intermediate 13) [ka]

[0206] To a solution of intermediate 12 (0.80 g, 3.66 mmol) in anhydrous THF (4 mL) and anhydrous tBuOH (4 mL) at 0° C., nitroethane (0.65 mL, 11.0 mmol) and tBuOK (41 mg, 0.37 mmol) were added. The mixture was stirred at room temperature for 2 h, and then it was dissolved in Et 2 Dilute with 25 mL of saturated NH 4 The combined aqueous layer was washed with Et 2 The mixture was extracted with 25 mL of 1H2O. The organic layers were combined and concentrated in vacuo to give the crude material (1.17 g) as a colorless oil. The crude material was dissolved in anhydrous DCM (20 mL) at 0° C. and methanesulfonyl chloride (0.30 mL, 3.92 mmol) was added and stirred for 5 min. TEA (1.09 mL, 7.84 mmol) was added at 0° C. and stirred at room temperature for 15 min. Saturated NH 4 Aqueous Cl was added and the mixture was extracted with DCM (2x15mL). The combined organic layers were concentrated in vacuo. The product was purified by column chromatography using a silica cartridge (0-10% EtOAc in cHex) to give the title compound (594mg, 2.16mmol, 55% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl 3) δ 7.37 - 7.29 (m, 2H), 7.28 - 7.17 (m, 4H), 4.26 (dd, J = 6.0, 1.2 Hz, 2H), 3.72 (t, J = 3.1 Hz, 1H), 2.58 (tt, J = 12.0, 3.7 Hz, 1H), 2.26 (q, J = 1.2 Hz, 3H), 2.12 - 2.02 (m, 2H), 1.85 (qd, J = 12.9, 3.4 Hz, 2H), 1.74 - 1.66 (m, 2H), 1.66 - 1.51 (m, 2H).

[0207] 3-Methyl-1-(3-nitro-1-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 14) [ka]

[0208] 3-Methylpyridin-2(1H)-one (106 mg, 0.97 mmol) was suspended in THF (3 mL) and tBuOK (65 mg, 0.58 mmol) and 18-Crown-6 (51 mg, 0.19 mmol) were added at 0° C. The reaction mixture was stirred for 1 h and cooled to −50° C., then intermediate 13 (150 mg, 0.48 mmol) in THF (3 mL) was added and the reaction mixture was stirred at −50° C. for 15 min. The solution was diluted with H 2 The mixture was diluted with O and extracted with EtOAc. The aqueous layer was evaporated in vacuo to give a crude product which was purified by column chromatography using a silica cartridge (0-5% methanol in DCM) to give the title compound (165 mg, 0.43 mmol, 89% yield). [M+H] + m / z 385.2

[0209] 1-(3-amino-1-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl)-3-methyl-1,2-dihydropyridin-2-one (Intermediate 15) [ka]

[0210] Intermediate 15 was prepared from intermediate 14 (164 mg, 0.43 mmol) following the procedure described for intermediate 9 to give the title compound (168 mg, quantitative yield) as a white solid. [M+H] + m / z 355.2

[0211] N-[(2S,3S)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3a), N-[(2R,3R)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3b), N-[(2R,3S)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3c), and N-[(2S,3R)-3-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)-4-{[(CIS)-4-phenylcyclohexyl]oxy}butan-2-yl]methanesulfonamide (3d) [ka]

[0212] Examples 3a, 3b, 3c, and 3d were prepared starting from intermediate 15 (145 mg, 0.31 mmol) according to the procedure described for Example 1, followed by preparative HPLC (MDAP Waters, column: xBridge C18 (30x100 mm, 3 μm). Conditions: [A: 10 mM NH 4 HCO 3 The aqueous solution was dissolved in NH 3[Adjust pH to 10 with 10.0 mL / min], [B: MeCN]. Gradient: 49.0% B to 51.0% B in 10 min (flow rate: 40.00 mL / min) gave fraction A (15 mg) and fraction B (15 mg). During the chiral separation using one of the conditions reported above, isomer 1 was assigned to the first eluting compound and isomer 2 to the second eluting compound.

[0213] Fraction A was subjected to chiral separation (Chiralpak AD-H, 25x2.0cm, 5μm, 70 / 30 n-Hexane: (ethanol / methanol 1:1 + 0.1% IPA, flow rate: 17mL / min)) to give Example 41 (5.8mg, 0.013mmol, yield 4%, 100%ee, rt 7.0min) and Example 42 (6.2mg, 0.014mmol, yield 5%, 100%ee, rt 10.9min).

[0214] Fraction B was subjected to chiral separation (Chiralpak AD-H, 25x2.0cm, 5μm, 55 / 45 n-Hexane: (ethanol / methanol 1:1 + 0.1% IPA, flow rate: 17mL / min)) to give Example 43 (4.6mg, 0.011mmol, yield 3%, 100%ee, rt 6.4min) and Example 44 (4.6mg, 0.011mmol, yield 3%, 100%ee, 10.5min) as white solids. [Table 6-1] [Table 6-2]

[0215] Example 4: N-[2-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (4) [ka] Methyl-2-bromo-3-{[(CIS)-4-phenylcyclohexyl]oxy}prop-2-enoate (Intermediate 16) [ka]

[0216] To a solution of pyridinium tribromide (4.40 g, 13.7 mmol) in anhydrous THF (30 mL) was added Intermediate 1 (3.41 g, 13.1 mmol) in anhydrous THF (2x10 mL) at 0°C. The reaction was allowed to warm to room temperature and stirred for 0.5 h. The solution was cooled to 0°C and then TEA (3.6 mL, 26.2 mmol) was added. The reaction mixture was allowed to warm to room temperature for 0.5 h. The reaction was stirred for 2 h at 37°C. 2 The mixture was quenched with O (20 mL) and extracted with DCM (3x75 mL). The combined organic layers were washed with MgSO 4 The mixture was dried at 4° C., filtered and concentrated in vacuo. The product was purified by column chromatography using a silica cartridge (0-10% EtOAc in heptane) to give the title compound (3.50 g, 10.32 mmol, 79% yield) as an off-white solid. [M+H] + m / z 339.2 & 341.2

[0217] Methyl-2-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}prop-2-enoate (Intermediate 17) [ka]

[0218] A solution of intermediate 16 (75 mg, 0.22 mmol) and (2-methoxy-3-pyridyl)boronic acid (51 mg, 0.33 mmol) in 2M Na 2 CO 3 A solution of water (0.33 mL, 0.66 mmol) and 1,4-dioxane (0.4 mL) was diluted with N 2 After degassing for 5 minutes, Pd 2 (dba) 3(51 mg, 0.055 mmol) and XPhos (53 mg, 0.11 mmol) were added. The reaction mixture was heated at 100° C. for 1 h. The reaction was filtered through Celite and washed with EtOAc. The combined organic layers were concentrated in vacuo and purified by column chromatography using a silica cartridge (0-20% EtOAc in heptane) to give the title compound (70 mg, 0.19 mmol, 87% yield) as a dark red gum. [M+H] + m / z 368.3

[0219] 3-(1-Hydroxy-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1-methyl-1,2-dihydropyridin-2-one (Intermediate 18) [ka]

[0220] Intermediate 18 was prepared from intermediate 17 (200 mg, 0.54 mmol) following the procedure described for intermediate 3 to give the title compound (232 mg, quantitative yield). [M+H] + m / z 342.4

[0221] 3-(1-Hydroxy-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1-methyl-1,2-dihydropyridin-2-one (Intermediate 19) [ka]

[0222] Intermediate 19 was prepared from intermediate 18 (388 mg, 1.14 mmol) following the procedure described for intermediate 4 to give the title compound (410 mg, quantitative yield). [M+H] + m / z 367.4

[0223] 3-(1-Hydroxy-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1-methyl-1,2-dihydropyridin-2-one (Intermediate 20) [ka]

[0224] Intermediate 20 was prepared from intermediate 19 (410 mg, 1.12 mmol) following the procedure described for intermediate 5 to give the title compound (94 mg, 0.28 mmol, 25% yield). [M+H] + m / z 341.4

[0225] N-[2-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (4) [ka]

[0226] Example 4 was prepared from Intermediate 20 (71 mg, 0.21 mmol) following the procedure described for Example 1 to afford the title compound (35 mg, 0.082 mmol, 40% yield) as a white solid.

[0227] The enantiomers were purified by chiral purification using Chiralpak columns (AD-H, IC, OJ-H) in the mixtures n-hexane / EtOH, n-hexane / (EtOH+0.1% iPrNH 2 ), n-Hexane / (EtOH / MeOH 1:1+0.1% iPrNH 2 ) in ratios ranging from 35:65 to 70:30. During the course of the chiral separation using one of the conditions reported above, isomer 1 was assigned to the first eluting compound and isomer 2 to the second eluting compound. [Table 7-1] [Table 7-2]

[0228] Example 5a: N-[2-(1,5-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (5a) [ka] 1,5-Dimethyl-3-(1-nitro-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 21) [ka]

[0229] To a solution of 3-bromo-1,5-dimethylpyridin-2-one (93 mg, 0.46 mmol) in anhydrous THF (2 mL) at -78 °C was added dropwise 2.5 M nBuLi in THF (0.18 mL, 0.46 mmol). The solution was stirred at -78 °C for 45 min. A solution of intermediate 7 (100 mg, 0.38 mmol) in THF (2 mL) was added dropwise and the solution was stirred at -78 °C for 30 min. The reaction was purified with saturated NH 4 The mixture was quenched at -78 °C by addition of aqueous Cl and allowed to reach room temperature. The solution was diluted with EtOAc and H 2 The mixture was washed with O. The organic layer was evaporated in vacuo and the product was purified by column chromatography using a silica cartridge (0-100% EtOAc in cHex) to give the title compound (58 mg, 0.15 mmol, 39% yield) as a pale yellow oil. [M+H] + m / z 385.3.

[0230] Intermediate 21a [ka]

[0231] 3-[1-[[4-(3-fluorophenyl)cyclohexoxy]methyl]-2-nitro-ethyl]-1,5-dimethyl-pyridin-2-one

[0232] A solution of 3-bromo-1,5-dimethyl-1,2-dihydropyridin-2-one (145 mg, 0.72 mmol) in THF (2.1 mL) was 2 Under atmospheric conditions, a 1.3 M solution of isopropylmagnesium chloride lithium chloride complex in THF (0.55 mL, 0.72 mmol) was added at room temperature. After the mixture was stirred for 10 min, CuI (150 mg, 0.79 mmol) was added and the reaction mixture was stirred for 1 h. After consumption of the starting material, a solution of 1-fluoro-3-[4-[(E)-3-nitroallyloxy]cyclohexyl]benzene (200 mg, 0.72 mmol) in THF (0.7 mL) was added and the reaction mixture was stirred at room temperature for 2 h. The mixture was diluted with saturated NH 4 The solution was quenched at room temperature by the addition of aqueous Cl. The solution was diluted with EtOAc and H 2 The organic layer was evaporated in vacuo to give the title compound (247 mg, 0.61 mmol, 86% yield) as a yellow oil. [M+H] + m / z 403.9

[0233] Intermediate 21b [ka]

[0234] 5-Methyl-3-(1-nitro-3-{[(CIS)-4-(3-fluorophenyl)cyclohexyl]oxy}propan-2-yl)-1,2-dihydropyridin-2-one

[0235] To a solution of 2-methoxy-5-methyl-3-(1-nitro-3-{[(CIS)-4-(3-fluorophenyl)cyclohexyl]oxy}propan-2-yl)pyridine (283 mg, 0.41 mmol) (prepared from 3-bromo-2-methoxy-5-methylpyridine according to the same procedure described for the synthesis of intermediate 21) in acetic acid (2 mL) was added KI (406 mg, 2.45 mmol). The emulsion was stirred at 90° C. for 18 h, and the mixture was then cooled to room temperature with saturated NaHCO 3 EtOAc was added and the mixture was poured into NaHCO 3 The organic phase was dried (Na 2 SO 4 ) and evaporated in vacuo. The product was purified by column chromatography (DCM / MeOH 100:0 to 95:5) using a 12 g silica cartridge to give the title compound (163 mg, quantitative yield) as a red-brown oil. [M+H] + m / z 389.4

[0236] Intermediate 21c [ka]

[0237] 2-[5-methyl-3-(1-nitro-3-{[(CIS)-4-(3-fluorophenyl)cyclohexyl]oxy}propan-2-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetonitrile Intermediate 21b (50 mg, 0.13 mmol) and K 2 CO 3 To a stirred suspension of (0.04 g, 0.26 mmol) in DMF (1 mL) was added 2-bromoacetonitrile (0.02 mL, 0.26 mmol) and the mixture was stirred at room temperature for 2 h. The mixture was diluted with EtOAc and washed with water. The organic layer was dried through a hydrophobic funnel and evaporated in vacuo to give the title compound (65 mg, quantitative yield) as a brown oil. [M+H] + m / z 428.3

[0238] Intermediate 21d [ka]

[0239] 2-[5-methyl-3-(1-nitro-3-{[(CIS)-4-(3-fluorophenyl)cyclohexyl]oxy}propan-2-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetonitrile

[0240] A solution of 5-methylpyrazolo[1,5-a]pyridine (104 mg, 0.79 mmol) was heated at −78 °C in N 2 A 2.5 M solution of nBuLi in hexane (0.34 mL, 0.86 mmol) was added under atmospheric pressure. The mixture was stirred for 30 min, and then intermediate 7 (200 mg, 0.72 mmol) was added and the reaction mixture was stirred at −78° C. for 1 h. The mixture was diluted with saturated NH 4 The mixture was quenched by addition of aqueous Cl and washed with EtOAc. The organic layer was dried through a hydrophobic funnel and evaporated in vacuo. The product was purified by column chromatography using a silica cartridge (cHex / EtOAc 100:0 to 70:30) to give the title compound (231 mg, 0.56 mmol, 78% yield) as an orange oil. [M+H] + m / z 412.3

[0241] Intermediate 21e [ka]

[0242] [1-(difluoromethyl)-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]boronic acid

[0243] KOAc (5.77g, 58.82mmol), [Pd(dppf)Cl 2 ] (1.2 g, 1.47 mmol), 3-bromo-1-(difluoromethyl)-5-methyl-pyridin-2-one (7.0 g, 29.41 mmol), and B 2 Pin 2A mixture of (7.47 g, 29.41 mmol) in anhydrous CPME (100 mL) was 2 The mixture was degassed by vacuum cycle. The mixture was then stirred at 90° C. for 16 h. The reaction was cooled and filtered through a pad of Celite. The solution was concentrated in vacuo and the product was purified by column chromatography (H 2 The title compound (3 g, 14.78 mmol, 50% yield) was obtained as a white solid. [M+H] + m / z 204.1

[0244] Intermediate 21f [ka]

[0245] [1-(difluoromethyl)-5-methyl-2-oxo-3-pyridyl]boronic acid

[0246] N 2 A mixture of chlorobis(ethylene)rhodium dimer (7 mg, 0.02 mmol) and (rac)-BINAP (23 mg, 0.04 mmol) in toluene (2 mL) was stirred at room temperature for 1 h under atmospheric conditions. A solution of intermediate 21e (109 mg, 0.54 mmol) and 1-fluoro-3-[4-[(E)-3-nitroallyloxy]cyclohexyl]benzene (50 mg, 0.18 mmol) in toluene (0.5 mL) was added, followed by 0.75 M aqueous potassium hydroxide (0.12 mL, 0.09 mmol). The reaction mixture was stirred at 100° C. for 1 h. The mixture was filtered through a pad of Celite and washed with EtOAc. The organic layer was treated with saturated NaHCO 3 The mixture was washed with aqueous solution and then evaporated in vacuo. The product was purified by column chromatography using a silica cartridge (0-20% EtOAc in cHex) to give the title compound (20 mg, 0.05 mmol, 26% yield) as an orange oil. [M+H] + m / z 439.3

[0247] 3-(1-amino-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-1,5-dimethyl-1,2-dihydropyridin-2-one (Intermediate 22) [ka]

[0248] Intermediate 22 was prepared from intermediate 21 (58 mg, 0.15 mmol) according to the procedure described for intermediate 9 to give the title compound (39 mg, 0.11 mmol, 74% yield). [M+H] + m / z 355.2

[0249] N-[2-(1,5-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl]methanesulfonamide (5a) [ka]

[0250] Example 5a was prepared from intermediate 22 (39 mg, 0.11 mmol) following the procedure described for example 1 to give the title compound (9 mg, 0.022 mmol, 19% yield).

[0251] 2-(1-Methanesulfonamido-3-{[(CIS)-4-phenylcyclohexyl]oxy}propan-2-yl)-4,6-dimethylpyridin-1-ium-1-oleate (5j) [ka]

[0252] To a mixture of Example 5i (15 mg, 0.04 mmol) in DCM (1 mL) was added 3-chlorobenzenecarboperoxoic acid (13.32 mg, 0.05 mmol) and the mixture was stirred at room temperature for 3 h. 2 CO 3The mixture was stirred at room temperature for 10 min. The mixture was diluted with DCM and 2 The mixture was washed with O. The organic layer was evaporated in vacuo and the product was purified by column chromatography using a silica cartridge (0-5% methanol in DCM) to give the title compound (8 mg, 0.02 mmol, 53% yield) as a white solid.

[0253] The following examples were prepared according to the procedure described in Example 5a using the appropriate heterocyclic reagents. These starting materials are either prepared as described in the intermediates section, are commercially available, or can be prepared from commercially available reagents using conventional reactions known in the art. Examples 5c and 5d were prepared according to the same three-step procedure described for the synthesis of Example 5a, using F-phenylcyclohexanol instead of phenylcyclohexanol. Example 5e was prepared from intermediate 21c according to the same procedure described for the synthesis of Example 5a. Example 5g was prepared from intermediate 21d according to the same procedure described for the synthesis of Example 5a. Examples 5m-5w were prepared according to the same three-step procedure described for the synthesis of Example 5a, varying only the first step, where the appropriate nitroalkene derivative was reacted with the appropriate heterocyclic reagent according to the procedure used for intermediate 21a. Examples 5x-5ac were prepared following the same three-step procedure described for the synthesis of Example 5a, varying only the first step, which was carried out by reacting the appropriate nitroalkene derivative with intermediate 21e according to the procedure used for intermediate 21f. The F-analogues were prepared following the same procedure described for the synthesis of Example 5a, using F-phenylcyclohexanol instead of phenylcyclohexanol. The sulfonamide analogues were obtained by reacting the amine with the appropriate sulfonyl chloride according to the procedure used for the synthesis of Example 5a. The enantiomers were separated by chiral purification using Chiralpak columns (AD-H, AS-H, IC, OJ-H) from the mixtures n-hexane / EtOH, n-hexane / (EtOH+0.1% iPrNH 2), n-Hexane / (EtOH / MeOH 1:1+0.1% iPrNH 2 ) in ratios ranging from 35:65 to 70:30. During the course of the chiral separation using one of the conditions reported above, isomer 1 was assigned to the first eluting compound and isomer 2 to the second eluting compound. These products are reported in the table below. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 8-5] [Table 8-6] [Table 8-7] [Table 8-8] [Table 8-9] [Table 8-10] [Table 8-11] [Table 8-12]

[0254] Example 6a: N-(2-{5-methyl-6-oxo-1,6-dihydro-[3,3'-bipyridin]-1-yl}-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl)methanesulfonamide (6a) [ka] Example 2X (40 mg, 0.080 mmol), Cs 2 CO 3 (105 mg, 0.32 mmol), Pd(PPh 3 ) 4 To a mixture of 1,3-dioxaborolan-2-yl)pyridine (28 mg, 0.020 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (66 mg, 0.32 mmol) was added DMF (2 mL). 2 After degassing for 10 min by bubbling, it was stirred at 120° C. for 16 h. The mixture was diluted with EtOAc and 2 O and brine. The organic layer was evaporated in vacuo. The product was purified by column chromatography using a C18 cartridge (H 2 HO+formic acid 0.1% / MeCN+formic acid 0.1%, 95:5 to 40:60) followed by preparative HPLC (Mass Spectrometric Detection MS: MDAP Waters with ZQ2000, Column: xBridge C18 (30x100mm, 3μm), Conditions: [A2: 10mM NH 4 HCO 3 Aqueous solution, NH 3 to pH 10], [B2: MeCN], gradient: 43.0% B2 to 45.0% B2 in 10 min, flow rate: 40.00 mL / min) to give the title compound (12 mg, 0.024 mmol, 30% yield) as a white solid. [Table 9]

[0255] Example 7a: N-{2-[3-methyl-2-oxo-5-(1H-pyrazol-1-yl)-1,2-dihydropyridin-1-yl]-3-{[(CIS)-4-phenylcyclohexyl]oxy}propyl}methanesulfonamide (7a) [ka] Example 2X (40 mg, 0.080 mmol), pyrazole (22 mg, 0.32 mmol), Cu 2 O (1 mg, 0.010 mmol), and Cs 2 CO 3 (105 mg, 0.32 mmol) was added DMSO (2 mL). The suspension was 2 After degassing for 10 min by bubbling, it was stirred at 120° C. for 16 h. The mixture was diluted with EtOAc and 2 O and brine. The organic layer was evaporated in vacuo. The product was purified by column chromatography using a silica cartridge (cHex / EtOAc, 40:60 to 100:0) followed by preparative HPLC (MDAP Waters with mass spectrometry detection MS: ZQ2000, column: xBridge C18 (30x100mm, 3μm), conditions: [A2: 10mM NH 4 HCO 3 Aqueous solution, NH 3 to pH 10], [B2: MeCN], gradient: 45.0% B2 to 446.0% B2 in 10 min, flow rate: 40.00 mL / min) to give the title compound (12 mg, 0.024 mmol, 30% yield) as a white solid. [Table 10]

[0256] Example 8a: N-(3-{[1,1'-biphenyl]-3-yl}-2-(2-oxo-1,2-dihydropyridin-1-yl)propyl)methanesulfonamide (8a) [ka] Ethyl 2-(2-oxo-1,2-dihydropyridin-1-yl)acetate (Intermediate 23) [ka]

[0257] To a suspension of NaH (0.93 g, 38.92 mmol) in anhydrous DMF (40 mL) was added 2-pyridone (3.42 g, 35.93 mmol). The mixture was stirred for 10 min and then added to a solution of ethyl 2-bromoacetate (5.0 g, 29.94 mmol) in anhydrous DMF (35 mL). The reaction mixture was stirred at room temperature for 72 h, after which it was diluted with DCM and washed with saturated NaHCO 3 The mixture was washed with aqueous solution and brine. The organic layer was dried over a phase separator and evaporated in vacuo. The product was purified by column chromatography using a silica cartridge (0-100% EtOAc in cHex) to give the title compound (5.56 g, quantitative yield) as a pale yellow oil. [M+H] + m / z 182.0

[0258] Ethyl 3-{[1,1'-biphenyl]-3-yl}-2-(2-oxo-1,2-dihydropyridin-1-yl)propanoate (Intermediate 24) [ka]

[0259] To a solution of intermediate 23 (3.0 g, 16.56 mmol) in THF (83 mL) was added 1 M LiHMDS in hexane (24.84 mL, 24.84 mmol) at −78° C. After 15 min, 3-(bromomethyl)-1,1′-biphenyl (5.32 g, 21.52 mmol) was added and the mixture was stirred at −78° C. for 90 min. Saturated NH 4Cl solution (30 mL) was added and the reaction was allowed to warm to room temperature. The solution was acidified by addition of 1M HCl and extracted with EtOAc (3x250 mL). The organic layer was dried through a phase separator and evaporated in vacuo. The product was purified by column chromatography using a silica cartridge (0-50% EtOAc in cHex) to give the title compound (5.2 g, 14.97 mmol, 90% yield) as a pale yellow oil. [M+H] + m / z 348.2

[0260] 1-(1-{[1,1'-biphenyl]-3-yl}-3-hydroxypropan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 25) [ka]

[0261] To a solution of intermediate 24 (2.0 g, 5.76 mmol) in THF (41 mL) at -40 °C, 2 M LiBH 4 A solution of (4.32 mL, 8.64 mmol) in THF was added. The mixture was stirred at -40 °C for 1 h and at room temperature for 24 h. The reaction mixture was quenched with water (50 mL) and 1 M aqueous NaOH (25 mL), extracted with EtOAc (3x200 mL), and the combined organic layers were dried (Na 2 SO 4 ), which was evaporated in vacuo to give the title compound (2 g, quantitative yield) as a pale yellow oil. [M+H] + m / z 306.2

[0262] 1-(1-Azido-3-{[1,1'-biphenyl]-3-yl}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 26) [ka]

[0263] To a solution of intermediate 25 (100 mg, 0.33 mmol) in THF (3 mL) at 0 °C was added TEA (68 uL, 0.49 mmol) and MsCl (27 uL, 0.34 mmol). After 30 min, NaN 3 (64 mg, 0.98 mmol) and DMF (0.1 mL) were added at 0° C. The mixture was stirred at 60° C. for 1 h. 2 The mixture was diluted with 200 mL of HO (10 mL) and extracted with EtOAc (3x50 mL). The combined organic layers were evaporated in vacuo and the product was purified by column chromatography using a silica cartridge (0-30% EtOAc in cHex) to give the title compound (46 mg, 0.14 mmol, 42% yield) as a colorless oil. [M+H] + m / z 331.2

[0264] 1-(1-amino-3-{[1,1'-biphenyl]-3-yl}propan-2-yl)-1,2-dihydropyridin-2-one (Intermediate 27) [ka]

[0265] PPh 3 (73 mg, 0.28 mmol) in THF (0.5 mL) and H 2 To a solution of 1H2O (0.25 mL) was added intermediate 27 (46 mg, 0.14 mmol). The mixture was stirred at room temperature for 16 h. 2 O (10 mL) was added and the product was extracted with Et 2 The mixture was extracted with 20 mL of ethyl acetate (100 mL). The organic layer was dried (Na 2 SO 4 ) and evaporated in vacuo. The product was loaded onto an SCX cartridge as a solution in MeOH, which was then washed with MeOH and NH 3 Elution with MeOH gave the title compound (18 mg, 0.059 mmol, 42% yield) as a colorless oil. [M+H] + m / z 305.3

[0266] N-(3-{[1,1'-biphenyl]-3-yl}-2-(2-oxo-1,2-dihydropyridin-1-yl)propyl)methanesulfonamide (8a) [ka]

[0267] Example 8a was prepared from intermediate 27 (18 mg, 0.059 mmol) following the procedure described for example 1 to afford the title compound (5 mg, 0.013 mmol, 22% yield) as a colorless oil. [Table 11]

[0268] Embodiment 1. Compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, A is heteroaryl; L 1 -O-, -CR 5 R 6 - or a bond, L 2 -CR 5 R 6 and R 1 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR 7 R 8 or R 1 and R 2 form a heterocycle together with the atoms to which they are attached, R 2 , R 3 , R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R 2 and R 3together with the atoms to which they are attached form a carbocyclic or heterocyclic ring, or R 2 and R 4 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 5 and R 6 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen; or R 5 and R 6 form a carbocyclic or heterocyclic ring together with the atoms to which they are attached, R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R 7 and R 8 form a heterocycle together with the atoms to which they are attached, Y is cycloalkyl, heterocyclyl, heteroaryl or aryl; Z is absent, heteroaryl or aryl; L 1 But, bond or CR 5 R 6 wherein Z is heteroaryl or aryl, or a pharma- ceutically acceptable salt thereof; [ka] or a pharma- ceutically acceptable salt thereof, provided that:

[0269] 2.L 1 The compound of embodiment 1, wherein

[0270] 3.L 1 The compound of embodiment 1, wherein

[0271] 4.R 1 The compound of any one of embodiments 1-3, wherein is alkyl.

[0272] 5.R 1 is methyl.

[0273] 6.R 1 Ga-NR 7 R 8 The compound of any one of embodiments 1 to 3, wherein

[0274] 7.R 7 and R 8 The compound of embodiment 6, wherein is alkyl.

[0275] 8.R 2 , R 3 , R 4 The compound of any one of embodiments 1-7, wherein is hydrogen.

[0276] 9. The compound according to any one of embodiments 1-8, wherein Y is a 3-7 membered monocyclic cycloalkyl, a 5-8 membered bicyclic cycloalkyl, a 4-7 membered saturated heterocyclyl, a 5-8 membered bicyclic heterocyclyl, a 5-6 membered heteroaryl or phenyl.

[0277] 10. The compound according to any one of embodiments 1-9, wherein Z is a 5-10 membered heteroaryl or phenyl.

[0278] 11. The compound according to any one of embodiments 1-8, wherein Y and Z are phenyl.

[0279] 12. The compound according to any one of embodiments 1-8, wherein Y is cyclohexyl and Z is phenyl.

[0280] 13. Y and Z together: [ka] 12. The compound of embodiment 11, wherein

[0281] 14. The compound according to any one of embodiments 1-13, wherein A is a substituted or unsubstituted monocyclic or bicyclic nitrogen-containing heteroaryl.

[0282] 15. The compound of embodiment 14, wherein A is selected from the group consisting of: [ka] Here, n is an integer from 0 to 6, R 9 is hydrogen, alkyl, halogen, cyano, alkoxy, cycloalkyl, heterocyclyl, or heteroaryl; R 11 is alkyl, cycloalkyl or heterocyclyl.

[0283] 16. The compound according to embodiment 1, wherein said compound of formula (I) is selected from the group consisting of the compounds in Table 1.

[0284] 17. A pharmaceutical composition comprising a compound according to any one of embodiments 1 to 16 and a pharma- ceutically acceptable excipient.

[0285] 18. A method for treating a disease or disorder treatable by administration of an orexin agonist, comprising administering a therapeutically effective amount of a compound according to any one of embodiments 1-16 or a composition according to embodiment 17.

[0286] 19. A method for treating a sleep disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of embodiments 1 to 16 or a composition according to embodiment 17.

[0287] 20. A method for treating narcolepsy in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-16 or a composition according to embodiment 17.

[0288] 21. A method for treating hypersomnia in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1 to 16 or a composition according to embodiment 17.

[0289] 22. A method for reducing or treating excessive sleepiness in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-16 or a composition according to embodiment 17.

Claims

1. A compound of formula (I): 【Chemical 1】 or a pharmaceutically acceptable salt thereof, wherein in the formula,[[]] A is heteroaryl, L １ is —O—, —CR ５ R ６ — or a bond, L ２ is -CR ５ R ６ and R １ is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -NR ７ R ８ or R １ and R ２ together with the atoms to which they are attached form a heterocycle, R ２ 、 R ３ 、 R ４ is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or halogen, or R ２ and R ３ together with the atom to which they are attached form a carbocyclic or heterocyclic ring, or R ２ and R ４ together with the atom to which they are attached form a carbocyclic or heterocyclic ring, R ５ and R ６ each independently is hydrogen, alkyl, cycloalkyl, heterocyclyl, alkoxy, -O-cycloalkyl, -O-heterocyclyl, or halogen, or R ５ and R ６ together with the atom to which they are attached form a carbocyclic or heterocyclic ring, R ７ and R ８ are each independently hydrogen, alkyl, cycloalkyl, or heterocyclyl, or R ７ and R ８ together with the atom to which they are attached form a heterocycle, Y is cycloalkyl, heterocyclyl, heteroaryl or aryl, Z is absent, heteroaryl or aryl, and L １ is a bond or CR ５ R ６ In the case of, Z is heteroaryl or aryl, wherein each alkyl, alkoxy, cycloalkyl, heterocyclyl, heterocyclic ring, aryl, heteroaryl, and carbocyclic ring is independently optionally substituted, said compound, or a pharmaceutically acceptable salt thereof, 【Chemical 2】 provided that it is not, said compound, or a pharmaceutically acceptable salt thereof.

2. L １ The compound according to claim 1, wherein L is -O- or a bond.

3. R １ is alkyl, haloalkyl, cycloalkyl, alkylene-alkoxy, or -NR ７ R ８ The compound according to claim 1, wherein

4. R １ is alkyl, haloalkyl, or -NR ７ R ８ and the compound according to claim 3.

5. R ７ and R ８ The compound according to claim 1, wherein R and R are alkyl.

6. R ２ 、 R ３ 、 and R ４ is hydrogen, the compound according to claim 1.

7. The compound according to claim 1, wherein Y is a 3- to 7-membered monocyclic cycloalkyl, a 5- to 8-membered bicyclic cycloalkyl, a 4- to 7-membered saturated heterocyclyl, a 5- to 8-membered bicyclic heterocyclyl, a 5- to 6-membered heteroaryl or phenyl.

8. The compound according to claim 1, wherein Z is a 5- to 10-membered heteroaryl or phenyl.

9. The compound according to claim 8, wherein Z is phenyl substituted with one or two halogens.

10. (i) Y and Z are phenyl; or (ii) Y is cyclohexyl and Z is phenyl; The compound according to claim 1.

11. The compound according to claim 1, wherein A is a substituted or unsubstituted monocyclic or bicyclic nitrogen-containing heteroaryl.

12. The compound according to claim 11, wherein A is selected from the group consisting of: 【Chemical Formula 3-1】 [Chemical Formula 3-2] wherein n is an integer from 0 to 6, R ９ is hydrogen, alkyl, haloalkyl, haloalkoxy, halogen, cyano, alkoxy, cycloalkyl, heterocyclyl, or heteroaryl, R １１ is alkyl optionally substituted with cyano, haloalkyl, cycloalkyl or heterocyclyl.

13. The compound according to claim 12, wherein n is 1.

14. The compound according to claim 12, wherein n is 2.

15. A is 【Chemical 4】 The compound according to claim 12.

16. A is 【Chemical Formula 5】 The compound according to claim 12.

17. R ９ The compound according to claim 12, wherein R is alkyl or halogen.

18. R １１ The compound according to claim 12, wherein R is alkyl or haloalkyl.

19. The compound of formula (I) is selected from the group consisting of the following compounds: [Chemical Formula 6-1] 【Chemical Formula 6-2】 【Chemical Formula 6-3】 【Chemical Formula 6-4】 [Chemical Formula 6-5] 【Chemical Formula 6-6】 [Chemical Formula 6-7] 【Chemical Formula 6-8】 【Chemical Formula 6-9】 【Chemical Formula 6-10】 【Chemical Formula 6-11】 【Chemical Formula 6-12】 【Chemical Formula 6-13】 ​ 【Chemical Formula 6-15】 【Chemical Formula 6-16】 【Chemical Formula 6-17】 ​ 【Chemical Formula 6-19】 and pharmaceutically acceptable salts thereof, the compound according to claim 1.

20. The following compounds: 【Chemical Formula 7-1】 【Chemical Formula 7-2】 【Chemical Formula 7-3】 and pharmaceutically acceptable salts thereof, a compound selected from the group consisting of.

21. A pharmaceutical composition comprising the compound according to any one of claims 1 to 20 and a pharmaceutically acceptable excipient.

22. The pharmaceutical composition according to claim 21, for treating a disease or disorder treatable by administration of an orexin agonist.

23. The pharmaceutical composition according to claim 21 for treating sleep disorders.

24. (i) Narcolepsy; or (ii) Hypersomnia; or (iii) Excessive drowsiness; The pharmaceutical composition according to claim 21 for treating the same.

Images